. 2014 Nov 6;9(3):810-21.

doi: 10.1016/j.celrep.2014.09.055. Epub 2014 Oct 30.

Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells

Faye M Drawnel¹, Stefano Boccardo², Michael Prummer¹, Frédéric Delobel¹, Alexandra Graff³, Michael Weber¹, Régine Gérard¹, Laura Badi¹, Tony Kam-Thong¹, Lei Bu⁴, Xin Jiang⁴, Jean-Christophe Hoflack¹, Anna Kiialainen¹, Elena Jeworutzki¹, Natsuyo Aoyama⁵, Coby Carlson⁵, Mark Burcin¹, Gianni Gromo¹, Markus Boehringer¹, Henning Stahlberg³, Benjamin J Hall¹, Maria Chiara Magnone¹, Kyle Kolaja⁵, Kenneth R Chien⁶, Jacques Bailly¹, Roberto Iacone⁷

Affiliations

¹ Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.
² Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
³ Center for Cell Imaging and Nano Analytics, Biozentrum, Department for Biosystems Science and Engineering, University of Basel, 4058 Basel, Switzerland.
⁴ The Cardiovascular Research Center, Richard B. Simches Research Center, Massachusetts General Hospital, Suite 3201, Boston, MA 02114, USA.
⁵ Cellular Dynamics International, Madison, WI 53711, USA.
⁶ Departments of Cell and Molecular Biology and of Medicine Huddinge, Karolinska Institutet, 171 77 Stockholm, Sweden; Harvard Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.
⁷ Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland. Electronic address: roberto.iacone@roche.com.

PMID: 25437537
DOI: 10.1016/j.celrep.2014.09.055

Free article

Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells

Faye M Drawnel et al. Cell Rep. 2014.

Free article

. 2014 Nov 6;9(3):810-21.

doi: 10.1016/j.celrep.2014.09.055. Epub 2014 Oct 30.

Authors

Affiliations

¹ Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.
² Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
³ Center for Cell Imaging and Nano Analytics, Biozentrum, Department for Biosystems Science and Engineering, University of Basel, 4058 Basel, Switzerland.
⁴ The Cardiovascular Research Center, Richard B. Simches Research Center, Massachusetts General Hospital, Suite 3201, Boston, MA 02114, USA.
⁵ Cellular Dynamics International, Madison, WI 53711, USA.
⁶ Departments of Cell and Molecular Biology and of Medicine Huddinge, Karolinska Institutet, 171 77 Stockholm, Sweden; Harvard Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.
⁷ Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland. Electronic address: roberto.iacone@roche.com.

PMID: 25437537
DOI: 10.1016/j.celrep.2014.09.055

Abstract

Diabetic cardiomyopathy is a complication of type 2 diabetes, with known contributions of lifestyle and genetics. We develop environmentally and genetically driven in vitro models of the condition using human-induced-pluripotent-stem-cell-derived cardiomyocytes. First, we mimic diabetic clinical chemistry to induce a phenotypic surrogate of diabetic cardiomyopathy, observing structural and functional disarray. Next, we consider genetic effects by deriving cardiomyocytes from two diabetic patients with variable disease progression. The cardiomyopathic phenotype is recapitulated in the patient-specific cells basally, with a severity dependent on their original clinical status. These models are incorporated into successive levels of a screening platform, identifying drugs that preserve cardiomyocyte phenotype in vitro during diabetic stress. In this work, we present a patient-specific induced pluripotent stem cell (iPSC) model of a complex metabolic condition, showing the power of this technique for discovery and testing of therapeutic strategies for a disease with ever-increasing clinical significance.

PubMed Disclaimer

Cited by

Myocardial Calcium Handling in Type 2 Diabetes: A Novel Therapeutic Target.
Dattani A, Singh A, McCann GP, Gulsin GS. Dattani A, et al. J Cardiovasc Dev Dis. 2023 Dec 30;11(1):12. doi: 10.3390/jcdd11010012. J Cardiovasc Dev Dis. 2023. PMID: 38248882 Free PMC article. Review.
Modeling diabetic endothelial dysfunction with patient-specific induced pluripotent stem cells.
Gorashi R, Rivera-Bolanos N, Dang C, Chai C, Kovacs B, Alharbi S, Ahmed SS, Goyal Y, Ameer G, Jiang B. Gorashi R, et al. Bioeng Transl Med. 2023 Aug 30;8(6):e10592. doi: 10.1002/btm2.10592. eCollection 2023 Nov. Bioeng Transl Med. 2023. PMID: 38023728 Free PMC article.
Effects of non-coding RNAs and RNA-binding proteins on mitochondrial dysfunction in diabetic cardiomyopathy.
Potel KN, Cornelius VA, Yacoub A, Chokr A, Donaghy CL, Kelaini S, Eleftheriadou M, Margariti A. Potel KN, et al. Front Cardiovasc Med. 2023 Sep 1;10:1165302. doi: 10.3389/fcvm.2023.1165302. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37719978 Free PMC article. Review.
Detecting and measuring of GPCR signaling - comparison of human induced pluripotent stem cells and immortal cell lines.
Chen G, Obal D. Chen G, et al. Front Endocrinol (Lausanne). 2023 May 24;14:1179600. doi: 10.3389/fendo.2023.1179600. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37293485 Free PMC article. Review.
Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid system.
Cui S, Fang X, Lee H, Shin YJ, Koh ES, Chung S, Park HS, Lim SW, Lee KI, Lee JY, Yang CW, Chung BH. Cui S, et al. J Transl Med. 2023 Feb 22;21(1):138. doi: 10.1186/s12967-023-03992-0. J Transl Med. 2023. PMID: 36814269 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Associated data

Actions
- Search in PubMed
- Search in GEO

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations
- scite Smart Citations
Medical
- Genetic Alliance
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells

Affiliations

Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Associated data

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical